With more novel drugs being approved for the treatment of ovarian carcinoma (OC), the question remains to what extent patients benefit from anti-angiogenic treatment with bevacizumab, either in combination with poly (ADP-ribose) polymerase (PAPR) inhibitors or as single-agent maintenance. As fibroblast growth factor receptors and their ligands (FGFRs/FGFs) are key players in angiogenic signaling and have been linked to resistance to several drugs, we investigated the prognostic or …